US FDA clears Cardio3 BioSciences' IND for CHART-2 phase III heart failure trial pharmabiz.com The US Food and Drug Administration (FDA) has authorized the Cardio3 BioSciences' Investigational New Drug (IND) application for clinical testing of the company's proprietary regenerative medicine product C3BS-CQR-1 (C-Cure) as a treatment targeting ... |
